Problems and Controversies in the Management of Hematogenous Candidiasis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Hematogenous candidiasis is associated with substantial mortality and morbidity. Amphotericin B has routinely been used to treat this infection. However, tolerance of therapy with amphotericin B is limited by the drug's toxicity. The results of recently completed prospective randomized clinical studies comparing amphotericin B with fluconazole for the treatment of hematogenous candididiasis suggest that fluconazole is as effective as amphotericin B and that fluconazole is better tolerated by patients. Nevertheless, several questions remain to be answered regarding the optimal choice of antifungal agent for both nonneutropenic and neutropenic patients, the dosing schedule and duration of therapy, the role of combination antifungal therapy, and the efficacy of the lipid formulations of polyenes. Controversial issues with respect to the role of central venous catheters in the pathogenesis of hematogenous candidiasis, as well as the roles of cytokines and white blood cell transfusions in the treatment of neutropenic patients with hematogenous candidiasis, also need to be addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · cited 4×
“The results of two recent prospective randomized multicenter trials comparing fluconazole with amphotericin B suggest that fluconazole is as effective as amphotericin B in the management of hematogenous candidiasis [28, 29].”
BackgroundResultInfluentialHospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831 · cited 1×
“Hematogenous candidiasis is a life-threatening infection that is associated with an attributable mortality of 38% and a prolongation of hospital stay by as much as 30 days [1].”
BackgroundCandida Colonization and Subsequent Infections in Critically III Surgical Patients
Pittet, D., Monod, M., Suter, P. M., Frenk, E., & Auckenthaler, R. (1994) · Annals of Surgery · doi:10.1097/00000658-199412000-00008 · Cited by 798 · cited 1×
“source of hematogenous candidiasis; rather, the gastrointestinal tract is the source [46-50].”
BackgroundCandidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Risk Factors for Hospital-Acquired Candidemia: A Matched Case-Control Study
Wey, S. B. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100145030 · Cited by 369 · cited 1×
“Several risk factors have been associated with the development of hematogenous candidiasis, including colonization by Candida species [2-5]; the presence of neutropenia and/or immunosuppression [2-4, 6], diarrhea, or severe mucositis [3, 6]; previous surgical procedures (particularly complicated gastrointestinal surge…”
BackgroundNguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363 · cited 2×
“A number of small series and retrospective studies [20-25], as well as a large prospective observational study [26], have shown response rates of 60%-100% when fluconazole is administered for treatment of serious candidal infections (table 2).”
Price, M. F., LaRocco, M. T., & Gentry, L. O. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.6.1422 · Cited by 229 · cited 1×
“There have been some concerns, however, regarding the use of fluconazole to treat hematogenous candidiasis because the drug is fungistatic and has limited activity against certain Candida species [30, 31].”
Background
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Management and outcome of bloodstream infections due to Candida species in England and Wales
Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J., & Wilson, J. A. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(03)00085-9 · Cited by 187
Risk factors for death in patients with candidemia
Nucci, M., Colombo, A. L., Silveira, F., Richtmann, R., Salomão, R., Branchini, M. L., & Spector, N. (1998) · Infection Control & Hospital Epidemiology · doi:10.1086/647743 · Cited by 178
Pfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3518-3521.2002 · Cited by 132
Metadata
- Authors
- Uzun, O., & Anaissie, E. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-05-01
- Volume
- 22
- Issue
- Supplement_2
- Pages
- S95-S101
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2100111159
- Cited by
- 38
- References
- 7
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Problems and Controversies in the Management of Hematogenous Candidiasis. https://app.cochat.ai/papers/10.1093/clinids/22.supplement_2.s95
- The paper
- Uzun, O., & Anaissie, E. J. (1996). Problems and Controversies in the Management of Hematogenous Candidiasis. Clinical Infectious Diseases. https://doi.org/10.1093/clinids/22.supplement_2.s95
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.